Viehbacher Christopher
SEC Form 4 insider trading activity
Viehbacher Christopher has filed 3 SEC Form 4 filings (7 transaction rows) across 2 companies, including BRVE, BIIB, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 7, 2026.
On the most recent filing, Viehbacher Christopher is listed as Director at Braveheart Bio, Inc. Inside the rolling window, Viehbacher Christopher reported 1 open-market purchase totaling $1.5M in BRVE and no open-market sales.
Companies traded
Other insiders at BRVE
Insider Buying
$1.5M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Viehbacher Christopher made?
Viehbacher Christopher has filed 3 SEC Form 4 filings (7 transaction rows) across 2 companies, including BRVE, BIIB since 2025.
Which companies does Viehbacher Christopher trade?
Viehbacher Christopher has filed SEC Form 4 disclosures for 2 companies, including BRVE, BIIB.
When was Viehbacher Christopher's most recent SEC Form 4 filing?
Viehbacher Christopher's most recent SEC Form 4 filing on Tracefour is dated Aug 7, 2026.
What is Viehbacher Christopher's total buy and sell value in the current window?
Inside the rolling retention window, Viehbacher Christopher bought $1.5M and sold $0 based on SEC Form 4 filings.
What was Viehbacher Christopher's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 83,333 BRVE shares on 2026-08-07, worth $1.5M, per SEC Form 4 filings.